{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:26:04Z","timestamp":1790961964242,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2018,7,16]],"date-time":"2018-07-16T00:00:00Z","timestamp":1531699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2018,7,16]],"date-time":"2018-07-16T00:00:00Z","timestamp":1531699200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1007\/s00262-018-2207-z","type":"journal-article","created":{"date-parts":[[2018,7,16]],"date-time":"2018-07-16T03:26:53Z","timestamp":1531711613000},"page":"1461-1472","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":96,"title":["Phase I trial of Lipovaxin-MM, a novel dendritic cell-targeted liposomal vaccine for malignant melanoma"],"prefix":"10.1007","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3713-1373","authenticated-orcid":false,"given":"Tessa","family":"Gargett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Nazim","family":"Abbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Rolan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason D.","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharine M.","family":"Gosling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Ferrante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Ruszkiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines I. C.","family":"Atmosukarto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Altin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher R.","family":"Parish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,16]]},"reference":[{"issue":"S4","key":"2207_CR1","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/ajco.12431_4","volume":"11","author":"N Abbas","year":"2015","unstructured":"Abbas N, Rolan P, Price JD, Gosling KM, Atmosukarato IIC, Parish CR, Brown MP (2015) Final report of a phase I trial of lipovaxin-MM, a novel dendritic cell-targeted liposomal vaccine for malignant melanoma. Asia-Pacific J Clin Oncol 11(S4):46\u201353 [Abstract]","journal-title":"Asia-Pacific J Clin Oncol"},{"issue":"5","key":"2207_CR2","doi-asserted-by":"publisher","first-page":"E359","DOI":"10.1002\/ijc.29210","volume":"136","author":"J Ferlay","year":"2015","unstructured":"Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5):E359\u2013E386. https:\/\/doi.org\/10.1002\/ijc.29210","journal-title":"Int J Cancer"},{"issue":"36","key":"2207_CR3","doi-asserted-by":"publisher","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","volume":"27","author":"CM Balch","year":"2009","unstructured":"Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, Eggermont AM, Flaherty KT, Gimotty PA, Kirkwood JM, McMasters KM, Mihm MC, Morton DL, Ross MI, Sober AJ, Sondak VK (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27(36):6199\u20136206. https:\/\/doi.org\/10.1200\/JCO.2009.23.4799","journal-title":"J Clin Oncol"},{"issue":"43","key":"2207_CR4","doi-asserted-by":"publisher","first-page":"75675","DOI":"10.18632\/oncotarget.18523","volume":"8","author":"HR Keller","year":"2017","unstructured":"Keller HR, Zhang X, Li L, Schaider H, Wells JW (2017) Overcoming resistance to targeted therapy with immunotherapy and combination therapy for metastatic melanoma. Oncotarget 8(43):75675\u201375686. https:\/\/doi.org\/10.18632\/oncotarget.18523","journal-title":"Oncotarget"},{"issue":"4","key":"2207_CR5","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/nrc3258","volume":"12","author":"K Palucka","year":"2012","unstructured":"Palucka K, Banchereau J (2012) Cancer immunotherapy via dendritic cells. Nat Rev Cancer 12(4):265\u2013277. https:\/\/doi.org\/10.1038\/nrc3258","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"2207_CR6","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/nm1039","volume":"10","author":"CG Figdor","year":"2004","unstructured":"Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ (2004) Dendritic cell immunotherapy: mapping the way. Nat Med 10(5):475\u2013480. https:\/\/doi.org\/10.1038\/nm1039","journal-title":"Nat Med"},{"issue":"4","key":"2207_CR7","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1124\/pr.114.009456","volume":"67","author":"S Anguille","year":"2015","unstructured":"Anguille S, Smits EL, Bryant C, Van Acker HH, Goossens H, Lion E, Fromm PD, Hart DN, Van Tendeloo VF, Berneman ZN (2015) Dendritic Cells as Pharmacological Tools for Cancer Immunotherapy. Pharmacol Rev 67(4):731\u2013753. https:\/\/doi.org\/10.1124\/pr.114.009456","journal-title":"Pharmacol Rev"},{"key":"2207_CR8","doi-asserted-by":"publisher","first-page":"255","DOI":"10.3389\/fimmu.2014.00255","volume":"5","author":"L Cohn","year":"2014","unstructured":"Cohn L, Delamarre L (2014) Dendritic cell-targeted vaccines. Front Immunol 5:255. https:\/\/doi.org\/10.3389\/fimmu.2014.00255","journal-title":"Front Immunol"},{"key":"2207_CR9","doi-asserted-by":"publisher","first-page":"975","DOI":"10.2147\/IJN.S68861","volume":"10","author":"G Bozzuto","year":"2015","unstructured":"Bozzuto G, Molinari A (2015) Liposomes as nanomedical devices. Int J Nanomedicine 10:975\u2013999. https:\/\/doi.org\/10.2147\/IJN.S68861","journal-title":"Int J Nanomedicine"},{"key":"2207_CR10","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1146\/annurev.immunol.22.012703.104558","volume":"22","author":"TB Geijtenbeek","year":"2004","unstructured":"Geijtenbeek TB, van Vliet SJ, Engering A, t Hart BA, van Kooyk Y (2004) Self- and nonself-recognition by C-type lectins on dendritic cells. Annu Rev Immunol 22:33\u201354. https:\/\/doi.org\/10.1146\/annurev.immunol.22.012703.104558","journal-title":"Annu Rev Immunol"},{"issue":"5","key":"2207_CR11","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.4049\/jimmunol.168.5.2118","volume":"168","author":"A Engering","year":"2002","unstructured":"Engering A, Geijtenbeek TB, van Vliet SJ, Wijers M, van Liempt E, Demaurex N, Lanzavecchia A, Fransen J, Figdor CG, Piguet V, van Kooyk Y (2002) The dendritic cell-specific adhesion receptor DC-SIGN internalizes antigen for presentation to T cells. J Immunol 168(5):2118\u20132126","journal-title":"J Immunol"},{"issue":"4","key":"2207_CR12","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1182\/blood-2005-01-0318","volume":"106","author":"PJ Tacken","year":"2005","unstructured":"Tacken PJ, de Vries IJ, Gijzen K, Joosten B, Wu D, Rother RP, Faas SJ, Punt CJ, Torensma R, Adema GJ, Figdor CG (2005) Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody. Blood 106(4):1278\u20131285. https:\/\/doi.org\/10.1182\/blood-2005-01-0318","journal-title":"Blood"},{"issue":"7","key":"2207_CR13","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1097\/CJI.0b013e318135472c","volume":"30","author":"A Kretz-Rommel","year":"2007","unstructured":"Kretz-Rommel A, Qin F, Dakappagari N, Torensma R, Faas S, Wu D, Bowdish KS (2007) In vivo targeting of antigens to human dendritic cells through DC-SIGN elicits stimulatory immune responses and inhibits tumor growth in grafted mouse models. J Immunother 30(7):715\u2013726. https:\/\/doi.org\/10.1097\/CJI.0b013e318135472c","journal-title":"J Immunother"},{"issue":"3","key":"2207_CR14","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/BF00199156","volume":"25","author":"P Hersey","year":"1987","unstructured":"Hersey P, Edwards A, Coates A, Shaw H, McCarthy W, Milton G (1987) Evidence that treatment with vaccinia melanoma cell lysates (VMCL) may improve survival of patients with stage II melanoma. Treatment of stage II melanoma with viral lysates. Cancer Immunol Immunother 25(3):257\u2013265","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"2207_CR15","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ymeth.2006.05.027","volume":"40","author":"JG Altin","year":"2006","unstructured":"Altin JG, Parish CR (2006) Liposomal vaccines\u2013targeting the delivery of antigen. Methods 40(1):39\u201352. https:\/\/doi.org\/10.1016\/j.ymeth.2006.05.027","journal-title":"Methods"},{"issue":"2","key":"2207_CR16","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.bbamem.2005.09.003","volume":"1716","author":"CL van Broekhoven","year":"2005","unstructured":"van Broekhoven CL, Altin JG (2005) The novel chelator lipid 3(nitrilotriacetic acid)-ditetradecylamine (NTA(3)-DTDA) promotes stable binding of His-tagged proteins to liposomal membranes: potent anti-tumor responses induced by simultaneously targeting antigen, cytokine and costimulatory signals to T cells. Biochim Biophys Acta 1716(2):104\u2013116. https:\/\/doi.org\/10.1016\/j.bbamem.2005.09.003","journal-title":"Biochim Biophys Acta"},{"issue":"12","key":"2207_CR17","doi-asserted-by":"publisher","first-page":"4357","DOI":"10.1158\/0008-5472.CAN-04-0138","volume":"64","author":"CL van Broekhoven","year":"2004","unstructured":"van Broekhoven CL, Parish CR, Demangel C, Britton WJ, Altin JG (2004) Targeting dendritic cells with antigen-containing liposomes: a highly effective procedure for induction of antitumor immunity and for tumor immunotherapy. Cancer Res 64(12):4357\u20134365. https:\/\/doi.org\/10.1158\/0008-5472.CAN-04-0138","journal-title":"Cancer Res"},{"issue":"3","key":"2207_CR18","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1046\/j.1440-1711.2001.01010.x","volume":"79","author":"CL Van Broekhoven","year":"2001","unstructured":"Van Broekhoven CL, Altin JG (2001) A novel system for convenient detection of low-affinity receptor-ligand interactions: chelator-lipid liposomes engrafted with recombinant CD4 bind to cells expressing MHC class II. Immunol Cell Biol 79(3):274\u2013284. https:\/\/doi.org\/10.1046\/j.1440-1711.2001.01010.x","journal-title":"Immunol Cell Biol"},{"issue":"5","key":"2207_CR19","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/S0092-8674(00)80693-5","volume":"100","author":"TB Geijtenbeek","year":"2000","unstructured":"Geijtenbeek TB, Torensma R, van Vliet SJ, van Duijnhoven GC, Adema GJ, van Kooyk Y, Figdor CG (2000) Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses. Cell 100(5):575\u2013585","journal-title":"Cell"},{"issue":"1","key":"2207_CR20","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1002\/path.4318","volume":"233","author":"K Harbst","year":"2014","unstructured":"Harbst K, Lauss M, Cirenajwis H, Winter C, Howlin J, Torngren T, Kvist A, Nodin B, Olsson E, Hakkinen J, Jirstrom K, Staaf J, Lundgren L, Olsson H, Ingvar C, Gruvberger-Saal SK, Saal LH, Jonsson G (2014) Molecular and genetic diversity in the metastatic process of melanoma. J Pathol 233(1):39\u201350. https:\/\/doi.org\/10.1002\/path.4318","journal-title":"J Pathol"},{"issue":"21","key":"2207_CR21","doi-asserted-by":"publisher","first-page":"6386","DOI":"10.1158\/1078-0432.CCR-07-0486","volume":"13","author":"CL Slingluff","year":"2007","unstructured":"Slingluff CL, Petroni GR, Chianese-Bullock KA, Smolkin ME, Hibbitts S, Murphy C, Johansen N, Grosh WW, Yamshchikov GV, Neese PY, Patterson JW, Fink R, Rehm PK (2007) Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting. Clin Cancer Res 13(21):6386\u20136395. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-0486","journal-title":"Clin Cancer Res"},{"issue":"20","key":"2207_CR22","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.2174\/15680266113136660181","volume":"13","author":"PO Lang","year":"2013","unstructured":"Lang PO, Govind S, Bokum AT, Kenny N, Matas E, Pitts D, Aspinall R (2013) Immune senescence and vaccination in the elderly. Curr Top Med Chem 13(20):2541\u20132550","journal-title":"Curr Top Med Chem"},{"issue":"12","key":"2207_CR23","doi-asserted-by":"publisher","first-page":"e82967","DOI":"10.1371\/journal.pone.0082967","volume":"8","author":"B Weinberger","year":"2013","unstructured":"Weinberger B, Schirmer M, Matteucci Gothe R, Siebert U, Fuchs D, Grubeck-Loebenstein B (2013) Recall responses to tetanus and diphtheria vaccination are frequently insufficient in elderly persons. PLoS One 8(12):e82967. https:\/\/doi.org\/10.1371\/journal.pone.0082967","journal-title":"PLoS One"},{"issue":"4","key":"2207_CR24","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1002\/1097-0142(197510)36:4<1289::AID-CNCR2820360415>3.0.CO;2-P","volume":"36","author":"GC de Gast","year":"1975","unstructured":"de Gast GC, The TH, Schraffordt Koops H, Huiges HA, Oldhoff J, Nieweg HO (1975) Humoral and cell-mediated immune response in patients with malignant melanoma. I. In vitro lymphocyte reactivity to PHA and antigens following immunization. Cancer 36(4):1289\u20131297","journal-title":"Cancer"},{"issue":"7 Pt 2","key":"2207_CR25","doi-asserted-by":"publisher","first-page":"2359s","DOI":"10.1158\/1078-0432.CCR-05-2537","volume":"12","author":"G Lizee","year":"2006","unstructured":"Lizee G, Radvanyi LG, Overwijk WW, Hwu P (2006) Immunosuppression in melanoma immunotherapy: potential opportunities for intervention. Clin Cancer Res 12(7 Pt 2):2359s\u20132365s. https:\/\/doi.org\/10.1158\/1078-0432.CCR-05-2537","journal-title":"Clin Cancer Res"},{"issue":"9","key":"2207_CR26","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/nm1100","volume":"10","author":"SA Rosenberg","year":"2004","unstructured":"Rosenberg SA, Yang JC, Restifo NP (2004) Cancer immunotherapy: moving beyond current vaccines. Nat Med 10(9):909\u2013915. https:\/\/doi.org\/10.1038\/nm1100","journal-title":"Nat Med"},{"issue":"17","key":"2207_CR27","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","volume":"33","author":"MA Postow","year":"2015","unstructured":"Postow MA, Callahan MK, Wolchok JD (2015) Immune checkpoint blockade in cancer therapy. J Clin Oncol 33(17):1974\u20131982. https:\/\/doi.org\/10.1200\/JCO.2014.59.4358","journal-title":"J Clin Oncol"},{"issue":"10","key":"2207_CR28","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1586\/1744666X.2014.955851","volume":"10","author":"M Tucci","year":"2014","unstructured":"Tucci M, Stucci S, Passarelli A, Giudice G, Dammacco F, Silvestris F (2014) The immune escape in melanoma: role of the impaired dendritic cell function. Expert Rev Clin Immunol 10(10):1395\u20131404. https:\/\/doi.org\/10.1586\/1744666X.2014.955851","journal-title":"Expert Rev Clin Immunol"},{"issue":"1","key":"2207_CR29","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/icb.2015.58","volume":"94","author":"KM Hargadon","year":"2016","unstructured":"Hargadon KM, Bishop JD, Brandt JP, Hand ZC, Ararso YT, Forrest OA (2016) Melanoma-derived factors alter the maturation and activation of differentiated tissue-resident dendritic cells. Immunol Cell Biol 94(1):24\u201338. https:\/\/doi.org\/10.1038\/icb.2015.58","journal-title":"Immunol Cell Biol"},{"issue":"7559","key":"2207_CR30","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nature14404","volume":"523","author":"S Spranger","year":"2015","unstructured":"Spranger S, Bao R, Gajewski TF (2015) Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity. Nature 523(7559):231\u2013235. https:\/\/doi.org\/10.1038\/nature14404","journal-title":"Nature"},{"issue":"Suppl 3","key":"2207_CR31","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1053\/j.seminoncol.2015.10.002","volume":"42","author":"M Atkins","year":"2015","unstructured":"Atkins M (2015) Immunotherapy combinations with checkpoint inhibitors in metastatic melanoma: current approaches and future directions. Semin Oncol 42(Suppl 3):S12\u2013S19. https:\/\/doi.org\/10.1053\/j.seminoncol.2015.10.002","journal-title":"Semin Oncol"},{"issue":"2","key":"2207_CR32","first-page":"243","volume":"7","author":"KJ Harrington","year":"2001","unstructured":"Harrington KJ, Mohammadtaghi S, Uster PS, Glass D, Peters AM, Vile RG, Stewart JS (2001) Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clin Cancer Res 7(2):243\u2013254","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2207_CR33","first-page":"29","volume":"2","author":"JH Schiller","year":"1996","unstructured":"Schiller JH, Pugh M, Kirkwood JM, Karp D, Larson M, Borden E (1996) Eastern cooperative group trial of interferon gamma in metastatic melanoma: an innovative study design. Clin Cancer Res 2(1):29\u201336","journal-title":"Clin Cancer Res"},{"issue":"11","key":"2207_CR34","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1200\/JCO.1987.5.11.1804","volume":"5","author":"MS Ernstoff","year":"1987","unstructured":"Ernstoff MS, Trautman T, Davis CA, Reich SD, Witman P, Balser J, Rudnick S, Kirkwood JM (1987) A randomized phase I\/II study of continuous versus intermittent intravenous interferon gamma in patients with metastatic melanoma. J Clin Oncol 5(11):1804\u20131810","journal-title":"J Clin Oncol"},{"issue":"8","key":"2207_CR35","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1089\/10430349950017978","volume":"10","author":"J Nemunaitis","year":"1999","unstructured":"Nemunaitis J, Fong T, Burrows F, Bruce J, Peters G, Ognoskie N, Meyer W, Wynne D, Kerr R, Pippen J, Oldham F, Ando D (1999) Phase I trial of interferon gamma retroviral vector administered intratumorally with multiple courses in patients with metastatic melanoma. Hum Gene Ther 10(8):1289\u20131298. https:\/\/doi.org\/10.1089\/10430349950017978","journal-title":"Hum Gene Ther"},{"issue":"1","key":"2207_CR36","doi-asserted-by":"publisher","first-page":"81","DOI":"10.7150\/thno.7193","volume":"4","author":"H Kobayashi","year":"2013","unstructured":"Kobayashi H, Watanabe R, Choyke PL (2013) Improving conventional enhanced permeability and retention (EPR) effects; what is the appropriate target? Theranostics 4(1):81\u201389. https:\/\/doi.org\/10.7150\/thno.7193","journal-title":"Theranostics"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-018-2207-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-018-2207-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-018-2207-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T18:20:53Z","timestamp":1744136453000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-018-2207-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,16]]},"references-count":36,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["2207"],"URL":"https:\/\/doi.org\/10.1007\/s00262-018-2207-z","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,16]]},"assertion":[{"value":"14 August 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Jason D. Price, Katharine M. Gosling, and Ines I.C. Atmosukarto are employed by Lipotek Pty Ltd. Paul Rolan, Joseph Altin, and Christopher R. Parish are Lipotek shareholders. Paul Rolan and Ines I.C. Atmosukarto are Directors of Lipotek. All other authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The Royal Adelaide Hospital Human Research Ethics Committee provided specific written approval of the Clinical Protocol and its subsequent amendments before participants were enrolled to the study (RAH Protocol No: 081124). This study was performed in accordance with the Therapeutic Goods Administration (TGA) Note for Guidance on Good Clinical Practice (2000), the ethical rules contained in the National Statement on Ethical Conduct in Human Research (2007) and the Declaration of Helsinki (1964). The trial was registered with the Australia and New Zealand Clinical Trials Registry (ACTRN12610000149066).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and ethical standards"}},{"value":"Informed written consent was obtained from all patients before enrollment.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}